Dixon Mitchell Investment Counsel Inc. Boosts Stake in HCA Healthcare, Inc. $HCA

Dixon Mitchell Investment Counsel Inc. boosted its stake in shares of HCA Healthcare, Inc. (NYSE:HCA) by 2.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 75,803 shares of the company’s stock after buying an additional 1,699 shares during the period. HCA Healthcare accounts for about 1.2% of Dixon Mitchell Investment Counsel Inc.’s investment portfolio, making the stock its 27th biggest holding. Dixon Mitchell Investment Counsel Inc.’s holdings in HCA Healthcare were worth $35,431,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the stock. State Street Corp lifted its holdings in HCA Healthcare by 1.0% during the fourth quarter. State Street Corp now owns 7,566,643 shares of the company’s stock worth $3,532,563,000 after buying an additional 76,039 shares during the period. Capital World Investors increased its position in shares of HCA Healthcare by 0.8% during the fourth quarter. Capital World Investors now owns 4,999,422 shares of the company’s stock worth $2,334,040,000 after purchasing an additional 40,086 shares in the last quarter. Geode Capital Management LLC increased its position in shares of HCA Healthcare by 0.4% during the fourth quarter. Geode Capital Management LLC now owns 3,663,705 shares of the company’s stock worth $1,702,738,000 after purchasing an additional 13,565 shares in the last quarter. Norges Bank acquired a new position in shares of HCA Healthcare during the fourth quarter worth $1,262,513,000. Finally, Arrowstreet Capital Limited Partnership increased its position in shares of HCA Healthcare by 11.9% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 2,311,112 shares of the company’s stock worth $1,078,966,000 after purchasing an additional 245,887 shares in the last quarter. Hedge funds and other institutional investors own 62.73% of the company’s stock.

HCA Healthcare Stock Up 2.3%

Shares of NYSE HCA opened at $387.25 on Friday. The business’s 50 day moving average is $429.60 and its two-hundred day moving average is $473.48. The firm has a market cap of $85.91 billion, a price-to-earnings ratio of 13.32, a PEG ratio of 1.23 and a beta of 1.12. HCA Healthcare, Inc. has a 52-week low of $330.00 and a 52-week high of $556.52.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings results on Friday, April 24th. The company reported $7.15 EPS for the quarter, missing the consensus estimate of $7.19 by ($0.04). The business had revenue of $19.11 billion during the quarter, compared to analyst estimates of $19.09 billion. HCA Healthcare had a negative return on equity of 295.93% and a net margin of 8.89%.The business’s revenue was up 4.3% on a year-over-year basis. During the same quarter last year, the firm earned $6.45 EPS. HCA Healthcare has set its FY 2026 guidance at 29.100-31.500 EPS. Analysts anticipate that HCA Healthcare, Inc. will post 30.07 EPS for the current fiscal year.

HCA Healthcare Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 16th will be paid a $0.78 dividend. The ex-dividend date is Tuesday, June 16th. This represents a $3.12 annualized dividend and a dividend yield of 0.8%. HCA Healthcare’s payout ratio is 10.73%.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on HCA. Mizuho upped their target price on HCA Healthcare from $540.00 to $585.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Royal Bank Of Canada decreased their target price on shares of HCA Healthcare from $593.00 to $534.00 and set an “outperform” rating on the stock in a research note on Monday, April 27th. Leerink Partners reduced their price target on shares of HCA Healthcare from $573.00 to $500.00 and set an “outperform” rating on the stock in a research report on Monday, April 27th. JPMorgan Chase & Co. reduced their price target on shares of HCA Healthcare from $535.00 to $490.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 19th. Finally, Sanford C. Bernstein reduced their price target on shares of HCA Healthcare from $503.00 to $413.00 and set a “market perform” rating on the stock in a research report on Thursday, June 4th. Fifteen investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, HCA Healthcare has an average rating of “Moderate Buy” and a consensus price target of $506.14.

HCA Healthcare Company Profile

HCA Healthcare is a for‑profit operator of healthcare facilities headquartered in Nashville, Tennessee. Founded in 1968, the company owns and operates a network of hospitals and related healthcare facilities and has grown through organic expansion and acquisitions to become a large provider of inpatient and outpatient services.

The company’s core activities include the operation of acute care hospitals, freestanding surgical and emergency centers, and outpatient clinics. HCA’s services encompass inpatient care, surgical services, emergency medicine, diagnostic imaging and laboratory testing, and various outpatient and ambulatory care offerings.